TEM-1657

N/A

Report date: 2025/01/26 17:26:44
NME

Base Information

Drug NameTEM-1657
Drug Alias NameTEM-1657
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNuclear factor NF-kappa-B complex inhibitorsInterleukin-17 modulators
TargetsInterleukin-17Nuclear factor NF-kappa-B complex
Therapy Area/IndicationsPsoriasisDermatitis, AtopicCrohn Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTemisis Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesTemisis Therapeutics
Inactive CompaniesN/A
Active IndicationsPsoriasisDermatitis, AtopicCrohn Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A